Product Datasheet

MTH1 Antibody - BSA Free NB100-109SS

Unit Size: 0.05 ml

Aliquot and store at -20C or -80C. Avoid freeze-thaw cycles.

www.novusbio.com



technical@novusbio.com

Publications: 37

Protocols, Publications, Related Products, Reviews, Research Tools and Images at: www.novusbio.com/NB100-109

Updated 4/13/2025 v.20.1

Earn rewards for product reviews and publications.

Submit a publication at www.novusbio.com/publications Submit a review at www.novusbio.com/reviews/destination/NB100-109



NB100-109SS

MTH1 Antibody - BSA Free

Product Information	
Unit Size	0.05 ml
Concentration	1.0 mg/ml
Storage	Aliquot and store at -20C or -80C. Avoid freeze-thaw cycles.
Clonality	Polyclonal
Preservative	0.02% Sodium Azide
Isotype	IgG
Purity	Immunogen affinity purified
Buffer	PBS
Target Molecular Weight	18 kDa
Product Description	
Host	Rabbit
Gene ID	4521
Gene Symbol	NUDT1
Species	Human, Mouse, Rat
Reactivity Notes	Rat reactivity reported in scientific literature (PMID: 12706856).
Immunogen	A C-terminal peptide derived from human MTH1, conjugated to KLH. [UniProt# P36639]
Product Application Details	
Applications	Western Blot, Simple Western, Immunoblotting, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Immunohistochemistry-Frozen, Immunohistochemistry-Paraffin, Knockdown Validated, Knockout Validated, Single Cell Western
Recommended Dilutions	Western Blot 1:500, Simple Western 1:50, Immunohistochemistry 1:200, Immunocytochemistry/ Immunofluorescence 1:50-1:200, Immunohistochemistry- Paraffin 1:200, Immunohistochemistry-Frozen 1:200, Immunoblotting reported in scientific literature (PMID 21076467), Knockout Validated, Single Cell Western 100 ug/ml, Knockdown Validated
Application Notes	In WB, a band can be seen at approx. 18kDa. In Simple Western only 10 - 15 uL of the recommended dilution is used per data point. See <u>Simple Western Antibody Database</u> for Simple Western validation: Tested in A431 lysate 0.5 mg/mL, separated by Size, antibody dilution of 1:50, apparent MW was 24 kDa. Separated by Size-Wes, Sally Sue/Peggy Sue. The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.



HEK293T MTH1 K0

kDa

Images

Western Blot: MTH1 Antibody [NB100-109] - Western blot shows lysates of HEK293T human embryonic kidney parental cell line and MTH1 knockout (KO) HEK293T cell line. PVDF membrane was probed with 1:500 of Rabbit Anti-Human MTH1 Polyclonal Antibody (Catalog # NB100-109) followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog #HAF008). Specific band was detected for MTH1 at approximately 18 kDa (as indicated) in the parental HEK293T cell line, but is not detectable in the knockout HEK293T cell line. This experiment was conducted under reducing conditions.

Simple Western: MTH1 Antibody [NB100-109] - Simple Western lane view shows a specific band for MTH1 in 0.5 mg/ml of A431 lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.

Western Blot: MTH1 Antibody [NB100-109] - The cells from esophageal cancer cell lines: KYSE-450, EC109 and EC9706 (d, e), liver cancer cell lines: SMMC-7721, HepG2 and ZIP177 (f, g), gastric cancer cell lines: MGC-803, HGC-27, SGC-7901 and MKN45 (h, i), as well as the corresponding normal cell lines: Het-1A (d, e), L02 (f, g) and GES-1 (h, i) were cultured and lysed. The MTH1 protein levels were determined by Western Blot. GAPDH was used as a loading control. At least three independent experiments were performed for each group. j The cells indicated above were lysed and the total mRNA was extracted. The mRNA level of MTH1 was determined by RT-PCR. GAPDH was used as a control. At least three independent experiments were performed for each group. Image collected and cropped by Citeab from the following publication (Potent and specific MTH1 inhibitors targeting gastric cancer. Cell Death Dis (2019)) licensed under a CC-BY license.

Western Blot: MTH1 Antibody [NB100-109] - The antioxidant pathways are activated during EBV infection and are required for growth transformation. Freshly isolated B-lymphocytes infected with the transforming B95-8 strain of EBV were cultured for up to 2 weeks in the presence or absence of MTH1 inhibitors. Protein expression was monitored by western blots, cell proliferation and activation of the DDR were assessed by 3H-Thy incorporation and staining for I3H2AX, respectively. Representative western blots illustrating the expression of MTH1, MUTYH and OGG1 in ex vivo untreated B-cell and freshly EBV infected and SAC induced B blasts cultured for comparable times and showing similar levels of cell proliferation. Image collected and cropped by Citeab from the following publication (The Epstein-Barr virus nuclear antigen-1 upregulates the cellular antioxidant defense to enable B-cell growth transformation and immortalization. Oncogene (2020)) licensed under a CC-BY license.







	0 1
Immunocytochemistry/Immunofluorescence: MTH1 Antibody [NB100- 109] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X PBS + 0.05% Triton-X100. The cells were incubated with anti-MTH1 at 2 ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.	Copyright & 2018 Novus Biologicals
Western Blot: MTH1 Antibody [NB100-109] - FBNA1 promotes the	×
upregulation of oxidative DNA damage repair pathways in EBV converted cell lines and EBV positive BLs. Densitometry quantification of the specific bands. The intensity of the specific band in EBV positive cells relative the EBV-negative parental is shown. Image collected and cropped by Citeab from the following publication (The Epstein-Barr virus nuclear antigen-1 upregulates the cellular antioxidant defense to enable B-cell growth transformation and immortalization. <i>Oncogene</i> (2020)) licensed under a CC-BY license.	
Western Blot: MTH1 Antibody [NB100-109] - MTH1 antibody was tested	
in the labeled lanes.	1 2 3 4 5
	Lanes 1-3 NT2 cells Lanes 4-5 833K64CP9 cells Western Blot courtesy of Mark Kelley Indiana University
Western Blot: MTH1 Antibody [NB100-109] - Analysis of MTH1 in 1. Ntera2, 2. MCF7 cell lysate, 3. A431 cell lysate and 4. COS7 cell lysate.	250>
	150>
	100> 75>
	50>
	37>
	25>
	15>
	10> 1 2 3 4

www.novusbio.com



Immunocytochemistry/Immunofluorescence: MTH1 Antibody [NB100-109] - A431 cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton-X100. The cells were incubated with anti-MTH1 (NB100-109) at a 1:200 dilution overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:500 dilution. Alpha tubulin was used as a co-stain at a 1:1000 dilution and detected with an anti-mouse Dylight 550 (Red) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.

Western Blot: MTH1 Antibody [NB100-109] - MTH1 suppression reduces the two gastric cancer cell survival. MGC-803, HGC-27 and GES-1 cells were treated by MTH1 specific siRNA 1 and #2 for 72h. Non-targeting siRNA(NT) treatment was used as control. Western Blot analysis of the protein levels of MTH1, MUTYH, OGG1, p21, ATMpS1981 and p53pS15, after the cells were treated with siRNA#2. Densitometry shows relative protein expression normalized by GAPDH. Image collected and cropped by Citeab from the following publication (Potent and specific MTH1 inhibitors targeting gastric cancer. *Cell Death Dis* (2019)) licensed under a CC-BY license.

Western Blot: MTH1 Antibody [NB100-109] - Simultaneous suppression of MTH1 and MYH was efficiently achieved using a two-vector system. Steps of cell line establishment are illustrated here. Top 15% of cells expressing GFP and RFP670 were sorted to improve the knockdown efficiency. Expression levels of MYH and MTH1 were analyzed after 96h of treatment with shRNA set2. Data were double normalized with GAPDH and NT-shRNA control samples and expressed as percentage. Image collected and cropped by Citeab from the following publication (hMYH and hMTH1 cooperate for survival in mismatch repair defective T-cell acute lymphoblastic leukemia. Oncogenesis (2016)) licensed under a CC-BY license.

Simultaneous suppression of MTH1 & MYH was efficiently achieved using a two-vector system. (a) Steps of cell line establishment are illustrated here. Top 15% of cells expressing GFP & RFP670 were sorted to improve the knockdown efficiency. Expression levels of MYH & MTH1 were analyzed after 96 h of treatment with Dox in shRNA set1 (b) & shRNA set2 (c) using qRT–PCR analysis. Data were normalized to NTshRNA expressing cells & presented as mean±s.e.m. from three independent experiments in triplicate. To investigate the knockdown efficiency at protein level, western blot analysis was performed after 96 h of Dox treatment of cells with shRNA set1 (d) & shRNA set2 (e). Data were double normalized with GAPDH & NT-shRNA control samples & expressed as percentage. The graphs represent mean±s.e.m. from three independent experiments. P-values were calculated using one-way analysis of variance (ANOVA). *P<0.05, **P<0.01, ***P<0.001, ****P0.0001, NS, not significant. Image collected & cropped by CiteAb from the following publication

(https://pubmed.ncbi.nlm.nih.gov/27918552), licensed under a CC-BY license. Not internally tested by Novus Biologicals.







EBNA1 promotes the upregulation of oxidative DNA damage repair pathways in EBV converted cell lines & EBV positive BLs. a Representative western blots illustrating the expression of MTH1, OGG1, & MUTYH in pairs of EBV-negative & -positive cell lines. GAPDH was used as loading control. b Densitometry quantification of the specific bands. The intensity of the specific band in EBV positive cells relative the EBV-negative parental is shown. Mean ± SE of four independent experiments. c Representative western blots illustrating the expression of EBNA1, MTH1, OGG1, & MUTYH in the Mutu cell lines. d Densitometry quantification of expression in the EBV positive cell lines relative to the EBV-negative Mutu-30. Mean ± SE of four independent experiments Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31511648), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Cell death & G1 arrest in hMTH1-depleted cells were rescued by hMYH overexpression. DNA content of cells without (a) or with (b) γ 3-hMYH overexpression at 96 h of Dox treatment is shown in histograms & their corresponding cell cycle distribution are displayed in stacked bar charts in (c, d). The γ 3-hMYH overexpression was validated after 96 h of Dox treatment by western blotting. One representative membrane is displayed in e. The results are presented as mean±s.e.m. from at least two independent experiments in duplicate. P-values were calculated using one-way analysis of variance (ANOVA). *P<0.05, **P<0.01, NS, not significant. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/27918552), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

The antioxidant pathways are activated during EBV infection & are required for growth transformation. Freshly isolated B-lymphocytes infected with the transforming B95-8 strain of EBV were cultured for up to 2 weeks in the presence or absence of MTH1 inhibitors. Protein expression was monitored by western blots, cell proliferation & activation of the DDR were assessed by 3H-Thy incorporation & staining for yH2AX, respectively. a representative western blots illustrating the parallel increase of MTH1 & EBNA1 expression following EBV infection & mean ± SE of the intensity of the MTH1 specific band in five independent experiments. b Representative western blots illustrating the expression of MTH1, MUTYH & OGG1 in ex vivo untreated B-cell & freshly EBV infected & SAC induced B blasts cultured for comparable times & showing similar levels of cell proliferation. c Quantification of the specific bands. Relative expression is the ration between the intensity in the treated cells versus freshly harvested cells. The mean ± SE of three to four independent experiments is shown. d Inhibition of MTH1 prevents the establishment of EBV transformed lymphoblastoid cell lines. 3H-Thy incorporation was measured after culture of freshly EBV infected Blymphocytes in the presence of the indicated amounts of MTH1 inhibitors. Depending on the condition of the cultures harvesting was done after ten to fifteen days. e Inhibition of MTH1 strongly enhances the induction of DNA damage in freshly EBV infected cells. DNA damage was detected by vH2AX staining. f Mean ± SE of the % vH2AX positive cells in three independent experiments. *P < 0.05; **P < 0.01 Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31511648), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Page 5 of 18 v.20.1 Updated 4/13/2025





EBNA1 expression is associated with upregulation of MTH1 & oxidative damage repair pathways. The expression of MTH1, OGG1, & MUTYH was investigated by western blots & gPCR in BJAB-tTAE1 cells upon addition & withdrawal of doxycycline. a Representative western blots illustrating the correlation between the reversible down- & upregulation of MTH1 & EBNA1 in BJAB-tTAE1 cells upon addition & withdrawal of doxycycline. GAPDH was used as loading control. b Densitometry quantification of MTH1 & EBNA1 expression in BJAB-tTAE1 cells. The mean intensity of the MTH1 & EBNA1 specific bands relative to GAPDH in three independent experiments is shown in the figure. c Regression analysis of the relationship between expression levels of MTH1 & EBNA1. The data from three independent experiments were used for the plot. d Representative western blots illustrating the expression of MTH1, MUTYH, & OGG1 in BJAB-tTAE1 cells cultured for two weeks in the presence or absence of doxycycline. e Fold change is the ratio between the intensity of the specific band in cells cultured without or with doxycycline. The mean ± SD of four independent experiments is shown. f qPCR analysis of the levels of MTH1, OGG1, & MUTYH transcripts in BJAB-tTAE1 cells cultured for 2 weeks in the presence or absence of doxycycline. The mean ± SE of the fold change in six independent experiments each performed in triplicate is shown Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31511648), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

EBNA1 promotes the upregulation of oxidative DNA damage repair pathways in EBV converted cell lines & EBV positive BLs. a Representative western blots illustrating the expression of MTH1, OGG1, & MUTYH in pairs of EBV-negative & -positive cell lines. GAPDH was used as loading control. b Densitometry quantification of the specific bands. The intensity of the specific band in EBV positive cells relative the EBV-negative parental is shown. Mean ± SE of four independent experiments. c Representative western blots illustrating the expression of EBNA1, MTH1, OGG1, & MUTYH in the Mutu cell lines. d Densitometry quantification of expression in the EBV positive cell lines relative to the EBV-negative Mutu-30. Mean ± SE of four independent experiments Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31511648), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Simultaneous suppression of MTH1 & MYH was efficiently achieved using a two-vector system. (a) Steps of cell line establishment are illustrated here. Top 15% of cells expressing GFP & RFP670 were sorted to improve the knockdown efficiency. Expression levels of MYH & MTH1 were analyzed after 96 h of treatment with Dox in shRNA set1 (b) & shRNA set2 (c) using qRT–PCR analysis. Data were normalized to NTshRNA expressing cells & presented as mean±s.e.m. from three independent experiments in triplicate. To investigate the knockdown efficiency at protein level, western blot analysis was performed after 96 h of Dox treatment of cells with shRNA set1 (d) & shRNA set2 (e). Data were double normalized with GAPDH & NT-shRNA control samples & expressed as percentage. The graphs represent mean±s.e.m. from three independent experiments. P-values were calculated using one-way analysis of variance (ANOVA). *P<0.05, **P<0.01, ***P<0.001, ****PD0.0001, NS, not significant. Image collected & cropped by CiteAb from the following publication

(https://pubmed.ncbi.nlm.nih.gov/27918552), licensed under a CC-BY license. Not internally tested by Novus Biologicals.







Page 7 of 18 v.20.1 Updated 4/13/2025



cropped by CiteAb from the following publication

license. Not internally tested by Novus Biologicals.



Western Blot: MTH1 Antibody - BSA Free [NB100-109] - Compound MI-743 causes intracellular 8-oxo-dG accumulation & DNA damage.a MGC-803, HGC-27 & GES-1 cells were treated with DMSO or 5 µM MI-743 for 48 h. Intracellular 8-oxo-dG was stained with Cv3-conjugated avidin. DNA was counterstained with 4,6-diamidino-2-phenylindole (DAPI). Images were acquired at ×100 magnification by a Nikon Eclipse TE 2000 -S fluorescence microscope. At least three independent experiments were performed for each group. b MGC-803, HGC-27 & GES-1 cells were treated with DMSO or 10 µM MI-743 for 48 h & run in alkaline comet assay. Pictures were originally captured at ×40 magnification. H2O2 was used as positive control. c Tail moment was calculated by CometScore software. Three individual experiments were performed for each group. d-f Western blot analysis of the protein levels of MTH1, MUTYH, OGG1, p21, ATMpS1981 & p53pS15 in MGC-803, HGC-27 & GES-1 cells, treated with increasing concentrations of MI-743 (0, 1, 2, 4, 8 & 12 µM). g, h Densitometry shows relative protein expression normalized for GAPDH. Data are representative of three independent experiments. i-k Western Blot analysis of the protein levels of MTH1, MUTYH, OGG1, p21, ATMpS1981 & p53pS15 of protein lysates, isolated from MGC-803, HGC-27 & GES-1 cells, which were treated with 12 µM MI-743 for 0, 12, 24, 36 & 48 h. l, m Densitometry shows relative protein expression normalized for GAPDH. Data are presented as means ± SD. Three individual experiments were performed for each group. *P < 0.05, **P < 0.01, ***P < 0.001 as compared with the controls Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31164636), licensed under a CC-BY license. Not internally tested by Novus Biologicals. Western Blot: MTH1 Antibody - BSA Free [NB100-109] - Compound MI-743 causes intracellular 8-oxo-dG accumulation & DNA damage.a MGC-803, HGC-27 & GES-1 cells were treated with DMSO or 5 µM MI-743 for 48 h. Intracellular 8-oxo-dG was stained with Cv3-conjugated avidin. DNA was counterstained with 4,6-diamidino-2-phenylindole (DAPI). Images were acquired at ×100 magnification by a Nikon Eclipse TE 2000 -S fluorescence microscope. At least three independent experiments were performed for each group. b MGC-803, HGC-27 & GES-1 cells were treated with DMSO or 10 µM MI-743 for 48 h & run in alkaline comet assay. Pictures were originally captured at ×40 magnification. H2O2 was used as positive control. c Tail moment was calculated by CometScore software. Three individual experiments were performed for each group. d-f Western blot analysis of the protein levels of MTH1, MUTYH, OGG1, p21, ATMpS1981 & p53pS15 in MGC-803, HGC-27 & GES-1 cells, treated with increasing concentrations of MI-743 (0, 1, 2, 4, 8 & 12 µM). g, h Densitometry shows relative protein expression normalized for GAPDH. Data are representative of three independent experiments. i-k Western Blot analysis of the protein levels of MTH1, MUTYH, OGG1, p21, ATMpS1981 & p53pS15 of protein lysates, isolated from MGC-803, HGC-27 & GES-1 cells, which were treated with 12 µM MI-743 for 0, 12, 24, 36 & 48 h. l, m Densitometry shows relative protein expression normalized for GAPDH. Data are presented as means ± SD. Three individual experiments were performed for each group. *P < 0.05, **P < 0.01, ***P < 0.001 as compared with the controls Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31164636). licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Page 8 of 18 v.20.1 Updated 4/13/2025





Western Blot: MTH1 Antibody - BSA Free [NB100-109] - Characteristic D expression of MTH1 in human gastric cancer tissues & ten digestive tract cancer cell lines.a The total RNA from fresh human gastric cancer MTHI 18KD tissues was isolated by RNApure Tissue&Cell Kit. The mRNA level of 37KU MTH1 in human gastric cancer (Increased, n = 21, Decreased, n = 6 & GAPDH Unchanged, n = 8) & adjacent normal tissues (Con, n = 35) was Het-1A KYSE450 EC9706 EC109 determined by RT-PCR. The protein levels of MTH1 in human gastric (GC) & adjacent normal (GN) tissue sections were determined by immuchistochemistry (IHC) staining. The integral optical densities (IOD) were analyzed by Image-Pro Plus 6.0 software. b Representative IHC pictures of GC & GN. Scale bars, 50 µm. c IODs of GC & GN. n = 10 for each group. The cells from esophageal cancer cell lines: KYSE-450, EC109 & EC9706 (d, e), liver cancer cell lines: SMMC-7721, HepG2 & ZIP177 (f, g), gastric cancer cell lines: MGC-803, HGC-27, SGC-7901 & MKN45 (h, i), as well as the corresponding normal cell lines: Het-1A (d, e), L02 (f, g) & GES-1 (h, i) were cultured & lysed. The MTH1 protein levels were determined by Western Blot. GAPDH was used as a loading control. At least three independent experiments were performed for each group. j The cells indicated above were lysed & the total mRNA was extracted. The mRNA level of MTH1 was determined by RT-PCR. GAPDH was used as a control. At least three independent experiments were performed for each group. Data are presented as means \pm SD. The symbol *, ** or *** stands for P < 0.05, P < 0.01 or P < 0.001 compared with the controls or normal cell groups Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31164636), licensed under a CC-BY license. Not internally tested by Novus Biologicals. Western Blot: MTH1 Antibody - BSA Free [NB100-109] - Compound MI-12µM-MI-743(h) I 743 causes intracellular 8-oxo-dG accumulation & DNA damage.a MGC-24 36 48 n 12803, HGC-27 & GES-1 cells were treated with DMSO or 5 µM MI-743 for MTH 18KD 48 h. Intracellular 8-oxo-dG was stained with Cv3-conjugated avidin. DNA was counterstained with 4,6-diamidino-2-phenylindole (DAPI). OGG 47KD Images were acquired at ×100 magnification by a Nikon Eclipse TE 2000 -S fluorescence microscope. At least three independent experiments MUTYI 60KD were performed for each group. b MGC-803, HGC-27 & GES-1 cells were treated with DMSO or 10 µM MI-743 for 48 h & run in alkaline p23 24KDcomet assay. Pictures were originally captured at ×40 magnification. ATM pS1981 H2O2 was used as positive control. c Tail moment was calculated by 350KD CometScore software. Three individual experiments were performed for p53 pS15 53KD each group. d-f Western blot analysis of the protein levels of MTH1, MUTYH, OGG1, p21, ATMpS1981 & p53pS15 in MGC-803, HGC-27 & GAPDH 37KD GES-1 cells, treated with increasing concentrations of MI-743 (0, 1, 2, 4, GES-1 8 & 12 µM). g, h Densitometry shows relative protein expression normalized for GAPDH. Data are representative of three independent experiments. i-k Western Blot analysis of the protein levels of MTH1, MUTYH, OGG1, p21, ATMpS1981 & p53pS15 of protein lysates, isolated from MGC-803, HGC-27 & GES-1 cells, which were treated with 12 µM MI-743 for 0, 12, 24, 36 & 48 h. l, m Densitometry shows relative protein expression normalized for GAPDH. Data are presented as means ± SD. Three individual experiments were performed for each group. *P < 0.05, **P < 0.01, ***P < 0.001 as compared with the controls Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31164636), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Page 9 of 18 v.20.1 Updated 4/13/2025

Western Blot: MTH1 Antibody - BSA Free [NB100-109] - Characteristic expression of MTH1 in human gastric cancer tissues & ten digestive tract cancer cell lines.a The total RNA from fresh human gastric cancer tissues was isolated by RNApure Tissue&Cell Kit. The mRNA level of MTH1 in human gastric cancer (Increased, n = 21, Decreased, n = 6 & Unchanged, n = 8) & adjacent normal tissues (Con, n = 35) was determined by RT-PCR. The protein levels of MTH1 in human gastric (GC) & adjacent normal (GN) tissue sections were determined by immuohistochemistry (IHC) staining. The integral optical densities (IOD) were analyzed by Image-Pro Plus 6.0 software. b Representative IHC pictures of GC & GN. Scale bars, 50 µm. c IODs of GC & GN. n = 10 for each group. The cells from esophageal cancer cell lines: KYSE-450, EC109 & EC9706 (d, e), liver cancer cell lines: SMMC-7721, HepG2 & ZIP177 (f, g), gastric cancer cell lines: MGC-803, HGC-27, SGC-7901 & MKN45 (h, i), as well as the corresponding normal cell lines: Het-1A (d, e), L02 (f, g) & GES-1 (h, i) were cultured & lysed. The MTH1 protein levels were determined by Western Blot. GAPDH was used as a loading control. At least three independent experiments were performed for each group. j The cells indicated above were lysed & the total mRNA was extracted. The mRNA level of MTH1 was determined by RT-PCR. GAPDH was used as a control. At least three independent experiments were performed for each group. Data are presented as means \pm SD. The symbol *, ** or *** stands for P < 0.05, P < 0.01 or P < 0.001 compared with the controls or normal cell groups Image collected & cropped by CiteAb from the following publication

(https://pubmed.ncbi.nlm.nih.gov/31164636), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: MTH1 Antibody - BSA Free [NB100-109] - The antioxidant A pathways are activated during EBV infection & are required for growth transformation. Freshly isolated B-lymphocytes infected with the transforming B95-8 strain of EBV were cultured for up to 2 weeks in the presence or absence of MTH1 inhibitors. Protein expression was monitored by western blots, cell proliferation & activation of the DDR were assessed by 3H-Thy incorporation & staining for yH2AX, respectively. a representative western blots illustrating the parallel increase of MTH1 & EBNA1 expression following EBV infection & mean ± SE of the intensity of the MTH1 specific band in five independent experiments. b Representative western blots illustrating the expression of MTH1, MUTYH & OGG1 in ex vivo untreated B-cell & freshly EBV infected & SAC induced B blasts cultured for comparable times & showing similar levels of cell proliferation. c Quantification of the specific bands. Relative expression is the ration between the intensity in the treated cells versus freshly harvested cells. The mean ± SE of three to four independent experiments is shown. d Inhibition of MTH1 prevents the establishment of EBV transformed lymphoblastoid cell lines. 3H-Thy incorporation was measured after culture of freshly EBV infected Blymphocytes in the presence of the indicated amounts of MTH1 inhibitors. Depending on the condition of the cultures harvesting was done after ten to fifteen days. e Inhibition of MTH1 strongly enhances the induction of DNA damage in freshly EBV infected cells. DNA damage was detected by yH2AX staining. f Mean ± SE of the % yH2AX positive cells in three independent experiments. *P < 0.05; **P < 0.01 Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31511648), licensed under a CC-BY license. Not internally tested by Novus Biologicals.





Western Blot: MTH1 Antibody - BSA Free [NB100-109] - EBNA1 expression is associated with upregulation of MTH1 & oxidative damage repair pathways. The expression of MTH1, OGG1, & MUTYH was investigated by western blots & gPCR in BJAB-tTAE1 cells upon addition & withdrawal of doxycycline. a Representative western blots illustrating the correlation between the reversible down- & upregulation of MTH1 & EBNA1 in BJAB-tTAE1 cells upon addition & withdrawal of doxycycline. GAPDH was used as loading control. b Densitometry quantification of MTH1 & EBNA1 expression in BJAB-tTAE1 cells. The mean intensity of the MTH1 & EBNA1 specific bands relative to GAPDH in three independent experiments is shown in the figure. c Regression analysis of the relationship between expression levels of MTH1 & EBNA1. The data from three independent experiments were used for the plot. d Representative western blots illustrating the expression of MTH1. MUTYH, & OGG1 in BJAB-tTAE1 cells cultured for two weeks in the presence or absence of doxycycline. e Fold change is the ratio between the intensity of the specific band in cells cultured without or with doxycycline. The mean ± SD of four independent experiments is shown. f qPCR analysis of the levels of MTH1, OGG1, & MUTYH transcripts in BJAB-tTAE1 cells cultured for 2 weeks in the presence or absence of doxycycline. The mean ± SE of the fold change in six independent experiments each performed in triplicate is shown Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31511648), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: MTH1 Antibody - BSA Free [NB100-109] - MTH1 suppression reduces the two gastric cancer cell survival.MGC-803, HGC-27 & GES-1 cells were treated by MTH1 specific siRNA#1 & #2 for 72 h. Non-targeting siRNA(NT) treatment was used as control. a Levels of MTH1 protein then were determined by western blot. b The colony formations were recorded after the cells were treated with MTH1 siRNA#1 & #2 for 7 days. c Western Blot analysis of the protein levels of MTH1, MUTYH, OGG1, p21, ATMpS1981 & p53pS15, after the cells were treated with siRNA#2. f-h Densitometry shows relative protein expression normalized by GAPDH. d The Alkaline comets assay was performed after the cells were transfected with MTH1 siRNA#2 for 72 h. Pictures were originally captured at ×40 magnification by fluorescence microscope. Non-targeting siRNA(NT) or H2O2 treatment was used as a negative or a positive control, respectively. e Tail moment was calculated by CometScore software. Three individual experiments were performed for each group, i Relative cell viability was determined by MTT assay, after the cells were treated with MTH1 siRNA#1 & #2 with or without MI-743 combined with 100uM H2O2. Data are presented as means ± SD. Three individual experiments were performed for each group. The symbols * & #, ** & ## or ***and ### stand for P < 0.05, P < 0.01 or P < 0.001 compared with the controls Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31164636), licensed under a CC-BY

license. Not internally tested by Novus Biologicals.







Western Blot: MTH1 Antibody - BSA Free [NB100-109] - Characteristic expression of MTH1 in human gastric cancer tissues & ten digestive tract cancer cell lines.a The total RNA from fresh human gastric cancer tissues was isolated by RNApure Tissue&Cell Kit. The mRNA level of MTH1 in human gastric cancer (Increased, n = 21, Decreased, n = 6 & Unchanged, n = 8) & adjacent normal tissues (Con, n = 35) was determined by RT-PCR. The protein levels of MTH1 in human gastric (GC) & adjacent normal (GN) tissue sections were determined by immuchistochemistry (IHC) staining. The integral optical densities (IOD) were analyzed by Image-Pro Plus 6.0 software. b Representative IHC pictures of GC & GN. Scale bars, 50 µm. c IODs of GC & GN. n = 10 for each group. The cells from esophageal cancer cell lines: KYSE-450, EC109 & EC9706 (d, e), liver cancer cell lines: SMMC-7721, HepG2 & ZIP177 (f, g), gastric cancer cell lines: MGC-803, HGC-27, SGC-7901 & MKN45 (h, i), as well as the corresponding normal cell lines: Het-1A (d, e), L02 (f, g) & GES-1 (h, i) were cultured & lysed. The MTH1 protein levels were determined by Western Blot. GAPDH was used as a loading control. At least three independent experiments were performed for each group. j The cells indicated above were lysed & the total mRNA was extracted. The mRNA level of MTH1 was determined by RT-PCR. GAPDH was used as a control. At least three independent experiments were performed for each group. Data are presented as means \pm SD. The symbol *, ** or *** stands for P < 0.05, P < 0.01 or P < 0.001 compared with the controls or normal cell groups Image collected & cropped by CiteAb from the following publication

(https://pubmed.ncbi.nlm.nih.gov/31164636), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: MTH1 Antibody - BSA Free [NB100-109] - Generation of MTH1/HRASV12 BEAS2B cell lines used in this study(A). MTH1 levels are elevated in nonsmall cell lung tumors relative to adjacent normal tissue. Samples are part of a tissue array obtained from US Biomax. Tissue sections were photographed at 200X. MTH1 expression is seen as brown staining. (B). Schematic showing how cell lines for this study were generated. (C). Western blotting confirming high or low levels of HRASV12 expression in MTH1-overexpressing (pBp.MTH1) & control (pBp) BEAS2B cells. Actin is shown as a loading control. Samples were harvested & lysed approximately 19 days following transduction. Quantitation of HRAS fold-changes (pBp values set to 1) among the samples is shown below the immunoblot images. Fold changes were calculated using loading-normalized signal intensities determined from three independently run blots. (D). Western blotting confirming high & low levels of HRASV12 expression in MTH1-suppressed (shMTH1) & control (shGFP) BEAS2B cells. Actin is shown as a loading control. Samples were harvested & lysed approximately 19 days following transduction. Quantitation of HRAS fold-changes (shGFP values set to 1) among the samples is shown below the immunoblot images & was calculated using loading-normalized signal intensities determined from three independently run blots. Image collected & cropped by CiteAb from the following publication (https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.3447),

(https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.3447) licensed under a CC-BY license. Not internally tested by Novus Biologicals. Page 12 of 18 v.20.1 Updated 4/13/2025





Western Blot: MTH1 Antibody - BSA Free [NB100-109] - Compound MI-743 causes intracellular 8-oxo-dG accumulation & DNA damage.a MGC-803, HGC-27 & GES-1 cells were treated with DMSO or 5 µM MI-743 for 48 h. Intracellular 8-oxo-dG was stained with Cv3-conjugated avidin. DNA was counterstained with 4,6-diamidino-2-phenylindole (DAPI). Images were acquired at ×100 magnification by a Nikon Eclipse TE 2000 -S fluorescence microscope. At least three independent experiments were performed for each group. b MGC-803, HGC-27 & GES-1 cells were treated with DMSO or 10 µM MI-743 for 48 h & run in alkaline comet assay. Pictures were originally captured at ×40 magnification. H2O2 was used as positive control. c Tail moment was calculated by CometScore software. Three individual experiments were performed for each group. d-f Western blot analysis of the protein levels of MTH1, MUTYH, OGG1, p21, ATMpS1981 & p53pS15 in MGC-803, HGC-27 & GES-1 cells, treated with increasing concentrations of MI-743 (0, 1, 2, 4, 8 & 12 µM). g, h Densitometry shows relative protein expression normalized for GAPDH. Data are representative of three independent experiments. i-k Western Blot analysis of the protein levels of MTH1, MUTYH, OGG1, p21, ATMpS1981 & p53pS15 of protein lysates, isolated from MGC-803, HGC-27 & GES-1 cells, which were treated with 12 µM MI-743 for 0, 12, 24, 36 & 48 h. l, m Densitometry shows relative protein expression normalized for GAPDH. Data are presented as means ± SD. Three individual experiments were performed for each group. *P < 0.05, **P < 0.01, ***P < 0.001 as compared with the controls Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31164636), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: MTH1 Antibody - BSA Free [NB100-109] - Characteristic expression of MTH1 in human gastric cancer tissues & ten digestive tract cancer cell lines.a The total RNA from fresh human gastric cancer tissues was isolated by RNApure Tissue&Cell Kit. The mRNA level of MTH1 in human gastric cancer (Increased, n = 21, Decreased, n = 6 & Unchanged, n = 8) & adjacent normal tissues (Con, n = 35) was determined by RT-PCR. The protein levels of MTH1 in human gastric (GC) & adjacent normal (GN) tissue sections were determined by immuchistochemistry (IHC) staining. The integral optical densities (IOD) were analyzed by Image-Pro Plus 6.0 software. b Representative IHC pictures of GC & GN. Scale bars, 50 µm. c IODs of GC & GN. n = 10 for each group. The cells from esophageal cancer cell lines: KYSE-450, EC109 & EC9706 (d, e), liver cancer cell lines: SMMC-7721, HepG2 & ZIP177 (f, g), gastric cancer cell lines: MGC-803, HGC-27, SGC-7901 & MKN45 (h, i), as well as the corresponding normal cell lines: Het-1A (d, e), L02 (f, g) & GES-1 (h, i) were cultured & lysed. The MTH1 protein levels were determined by Western Blot. GAPDH was used as a loading control. At least three independent experiments were performed for each group. j The cells indicated above were lysed & the total mRNA was extracted. The mRNA level of MTH1 was determined by RT-PCR. GAPDH was used as a control. At least three independent experiments were performed for each group. Data are presented as means ± SD. The symbol *, ** or *** stands for P < 0.05, P < 0.01 or P < 0.001 compared with the controls or normal cell groups Image collected & cropped by CiteAb from the following publication

(https://pubmed.ncbi.nlm.nih.gov/31164636), licensed under a CC-BY license. Not internally tested by Novus Biologicals.





Western Blot: MTH1 Antibody - BSA Free [NB100-109] - Compound MI-743 causes intracellular 8-oxo-dG accumulation & DNA damage.a MGC-803, HGC-27 & GES-1 cells were treated with DMSO or 5 µM MI-743 for 48 h. Intracellular 8-oxo-dG was stained with Cv3-conjugated avidin. DNA was counterstained with 4,6-diamidino-2-phenylindole (DAPI). Images were acquired at ×100 magnification by a Nikon Eclipse TE 2000 -S fluorescence microscope. At least three independent experiments were performed for each group. b MGC-803, HGC-27 & GES-1 cells were treated with DMSO or 10 µM MI-743 for 48 h & run in alkaline comet assay. Pictures were originally captured at ×40 magnification. H2O2 was used as positive control. c Tail moment was calculated by CometScore software. Three individual experiments were performed for each group. d-f Western blot analysis of the protein levels of MTH1, MUTYH, OGG1, p21, ATMpS1981 & p53pS15 in MGC-803, HGC-27 & GES-1 cells, treated with increasing concentrations of MI-743 (0, 1, 2, 4, 8 & 12 µM). g, h Densitometry shows relative protein expression normalized for GAPDH. Data are representative of three independent experiments. i-k Western Blot analysis of the protein levels of MTH1, MUTYH, OGG1, p21, ATMpS1981 & p53pS15 of protein lysates, isolated from MGC-803, HGC-27 & GES-1 cells, which were treated with 12 µM MI-743 for 0, 12, 24, 36 & 48 h. l, m Densitometry shows relative protein expression normalized for GAPDH. Data are presented as means ± SD. Three individual experiments were performed for each group. *P < 0.05, **P < 0.01, ***P < 0.001 as compared with the controls Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31164636), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: MTH1 Antibody - BSA Free [NB100-109] - Screening of MTH1 inhibitors in vitro, MD simulations & binding free energy calculation of compound MI-743 & MTH1.a The structures, IC50 values & (b) percentage of MTH1 inhibition rate of the potential inhibitors MI-743, MI-401 & negative compound MI-929. c MGC-803 cells were treated with 50 µM compounds MI-743, MI-401, (S)-crizotinib or MI-929, respectively, collected & heated for 10 min from 43 to 61 °C. The cells were lysed & the protein levels of MTH1, OGG1, MUTYH or MTH2 were determined by western Blot. At least three independent experiments were performed for each group. Data are presented as means ± SD. d Predicted binding mode of compound MI-743 in MTH1 binding pocket (PDB code: 4N1U). Compound MI-743 is shown as green stick. The residues of MTH1 associated with MI-743 are shown in white. Hydrogen bonds are shown in magenta dash lines & the corresponding distances are given in Å. The RMSD value plots of the protein (MTH1) (e) & ligand (MI-743) (f) in the mutation & wild-type complex systems after 30 ns MD simulations. Binding models of compound MI-743 in MTH1 D119A (g), D120A (h), N33A (i) & W117A (j) mutations. k MM/PBSA binding free energy, estimated with the MTH1 wild-type & mutant systems obtained from the last 5 ns stable MD trajectory. I Flow diagram for the principle of detecting MTH1 activity. Since MTH1 can convert dGTP to dGMP & pyrophosphate, & the latter of which can be hydrolyzed to inorganic pyrophosphate by inorganic pyrophosphatase, the formed inorganic pyrophosphate can react with malachite green & ammonium molybdate to produce the green associated complex, the absorbance of which can be measured at 630 nm by PerkinElmer Envision microplate reader, indicating the activity of MTH1 Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31164636), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Page 14 of 18 v.20.1 Updated 4/13/2025





Publications

Valerie NCK, Sanjiv K, Mortusewicz O et Al. Coupling cellular drug-target engagement to downstream pharmacology with CeTEAM Nat Commun 2024-12-06 [PMID: 39643609]

Jianyu Shen, Emilio Guillén Mancina, Shenyu Chen, Theodora Manolakou, Helge Gad, Ulrika Warpman Berglund, Kumar Sanjiv, Thomas Helleday Mitotic MTH1 inhibitor TH1579 induces PD-L1 expression and inflammatory response through the cGAS-STING pathway Oncogenesis 2024-05-25 [PMID: 38796460]

Marlinde L. van den Boogaard, Rurika Oka, Anne Hakkert, Linda Schild, Marli E. Ebus, Michael R. van Gerven, Danny A. Zwijnenburg, Piet Molenaar, Lieke L. Hoyng, M. Emmy M. Dolman, Anke H. W. Essing, Bianca Koopmans, Thomas Helleday, Jarno Drost, Ruben van Boxtel, Rogier Versteeg, Jan Koster, Jan J. Molenaar Defects in 8-oxoguanine repair pathway cause high frequency of C > A substitutions in neuroblastoma Proceedings of the National Academy of Sciences of the United States of America 2021-09-07 [PMID: 34479993]

Ding Y, Gui X, Chu X et al. MTH1 protects platelet mitochondria from oxidative damage and regulates platelet function and thrombosis Nature Communications 2023-08-10 [PMID: 37563135] (Western Blot)

Sanjiv K, Calder n-Monta o JM, Pham TM et al. MTH1 Inhibitor TH1579 Induces Oxidative DNA Damage and Mitotic Arrest in Acute Myeloid Leukemia Cancer Research 2021-11-15 [PMID: 34593524] (Western Blot)

Henriksson S, CalderOn-MontaNo J, Solvie D et al. Overexpressed C-Myc Sensitize Cells to TH1579, an Mitotic Arrest and Oxidative DNA Damage Inducer Preprint 2022-08-22 [PMID: 36551206] (WB, Human)

Bialkowski K, Szpila A Specific 8-oxo-dGTPase activity of MTH1 (NUDT1) protein as a quantitative marker and prognostic factor in human colorectal cancer Free radical biology & medicine 2021-10-05 [PMID: 34624481]

Karsten S, Fiskesund R, Zhang XM Et al. MTH1 as a target to alleviate T cell driven diseases by selective suppression of activated T cells Cell death and differentiation 2021-08-27 [PMID: 34453118] (WB, Human)

Zhang L, Misiara L, Samaranayake GJ, et al. OGG1 co-inhibition antagonizes the tumor-inhibitory effects of targeting MTH1 Redox biology 2021-01-02 [PMID: 33450725] (WB, Human)

Arczewska KD, Krasuska W, Stachurska A et al. hMTH1 and GPX1 expression in human thyroid tissue is interrelated to prevent oxidative DNA damage DNA Repair (Amst.) 2020-08-20 [PMID: 32877752] (WB, Human)

Godoy PRDV, Pour Khavari A, Rizzo M et al. Targeting NRF2, Regulator of Antioxidant System, to Sensitize Glioblastoma Neurosphere Cells to Radiation-Induced Oxidative Stress Oxid Med Cell Longev 2020-06-15 [PMID: 32617133] (WB, Human)

Rudd SG, Gad H, Sanjiv K et al. MTH1 inhibitor TH588 disturbs mitotic progression and induces mitosis-dependent accumulation of genomic 8-oxodG Cancer Res. 2020-04-20 [PMID: 32312836]

More publications at http://www.novusbio.com/NB100-109





Procedures

Western Blot protocol for MTH1 Antibody (NB100-109) Western Blot Protocol

1. Perform SDS-PAGE on samples to be analyzed, loading 10-25 ug of total protein per lane.

2. Transfer proteins to PVDF membrane according to the instructions provided by the manufacturer of the membrane and transfer apparatus.

3. Stain the membrane with Ponceau S (or similar product) to assess transfer success, and mark molecular weight standards where appropriate.

4. Rinse the blot TBS -0.05% Tween 20 (TBST).

5. Block the membrane in 5% Non-fat milk in TBST (blocking buffer) for at least 1 hour.

6. Wash the membrane in TBST three times for 10 minutes each.

7. Dilute primary antibody in blocking buffer and incubate overnight at 4C with gentle rocking.

8. Wash the membrane in TBST three times for 10 minutes each.

9. Incubate the membrane in diluted HRP conjugated secondary antibody in blocking buffer (as per manufacturer's instructions) for 1 hour at room temperature.

10. Wash the blot in TBST three times for 10 minutes each (this step can be repeated as required to reduce background).

11. Apply the detection reagent of choice in accordance with the manufacturer's instructions.

Immunocytochemistry/Immunofluorescence Protocol for MTH1 Antibody (NB100-109)

Immunocytochemistry Protocol

Culture cells to appropriate density in 35 mm culture dishes or 6-well plates.

1. Remove culture medium and wash the cells briefly in PBS. Add 10% formalin to the dish and fix at room temperature for 10 minutes.

2. Remove the formalin and wash the cells in PBS.

3. Permeablize the cells with 0.1% Triton X100 or other suitable detergent for 10 min.

4. Remove the permeablization buffer and wash three times for 10 minutes each in PBS. Be sure to not let the specimen dry out.

5. To block nonspecific antibody binding, incubate in 10% normal goat serum from 1 hour to overnight at room temperature.

6. Add primary antibody at appropriate dilution and incubate overnight at 4C.

7. Remove primary antibody and replace with PBS. Wash three times for 10 minutes each.

8. Add secondary antibody at appropriate dilution. Incubate for 1 hour at room temperature.

9. Remove secondary antibody and replace with PBS. Wash three times for 10 minutes each.

10. Counter stain DNA with DAPi if required.



Immunohistochemistry-Paraffin Protocol for MTH1 Antibody (NB100-109)

Immunohistochemistry-Paraffin Embedded Sections

Antigen Unmasking:

Bring slides to a boil in 10 mM sodium citrate buffer (pH 6.0) then maintain at a sub-boiling temperature for 10 minutes. Cool slides on bench-top for 30 minutes (keep slides in the sodium citrate buffer at all times).

Staining:

- 1. Wash sections in deionized water three times for 5 minutes each.
- 2. Wash sections in PBS for 5 minutes.
- 3. Block each section with 100-400 ul blocking solution (1% BSA in PBS) for 1 hour at room temperature.
- 4. Remove blocking solution and add 100-400 ul diluted primary antibody. Incubate overnight at 4 C.
- 5. Remove antibody solution and wash sections in wash buffer three times for 5 minutes each.
- 6. Add 100-400 ul HRP polymer conjugated secondary antibody. Incubate 30 minutes at room temperature.
- 7. Wash sections three times in wash buffer for 5 minutes each.
- 8. Add 100-400 ul DAB substrate to each section and monitor staining closely.
- 9. As soon as the sections develop, immerse slides in deionized water.
- 10. Counterstain sections in hematoxylin.
- 11. Wash sections in deionized water two times for 5 minutes each.
- 12. Dehydrate sections.
- 13. Mount coverslips.





Novus Biologicals USA

10730 E. Briarwood Avenue Centennial, CO 80112 USA Phone: 303.730.1950 Toll Free: 1.888.506.6887 Fax: 303.730.1966 nb-customerservice@bio-techne.com

Bio-Techne Canada

21 Canmotor Ave Toronto, ON M8Z 4E6 Canada Phone: 905.827.6400 Toll Free: 855.668.8722 Fax: 905.827.6402 canada.inquires@bio-techne.com

Bio-Techne Ltd

19 Barton Lane Abingdon Science Park Abingdon, OX14 3NB, United Kingdom Phone: (44) (0) 1235 529449 Free Phone: 0800 37 34 15 Fax: (44) (0) 1235 533420 info.EMEA@bio-techne.com

General Contact Information

www.novusbio.com Technical Support: nb-technical@biotechne.com Orders: nb-customerservice@bio-techne.com General: novus@novusbio.com

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit www.novusbio.com/guarantee

Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/NB100-109

Earn gift cards/discounts by submitting a publication using this product: www.novusbio.com/publications

